Systematic Review of Quadrivalent Influenza Vaccine Cost-Effectiveness in Europe

Eight studies analyzing the cost-effectiveness of quadrivalent influenza vaccines (QIV) in the general European population since 2012 are synthesized. The review, authored by Bram Van Sassenbroeck, found QIVs were cost-effective in 18 out of 19 analyses at a threshold of €35,000 per QALY. It was last updated in April 2026.

Use Cases

• Compare cost-effectiveness outcomes across different willingness-to-pay thresholds like €20,000 and €35,000 per QALY.
• Analyze the impact of herd immunity as a factor in cost-effectiveness gains for non-targeted populations.
• Review modeling assumptions and funding sources (e.g., industry-funded studies) across the included analyses.
• Assess the clinical and epidemiological validity of data used in the 8 included studies.

Strengths

• Synthesizes findings from 8 distinct studies and 19 separate cost-effectiveness analyses.
• Provides specific quantitative results, such as 18/19 analyses meeting a €35,000/QALY threshold.

Limitations

• Limited scope with only 8 included studies, potentially reducing generalizability.
• Most analyses were industry-funded, which may introduce bias.
• The dataset is a 437.6 KB document, offering a summary review rather than raw analytical data.

Provenance

Source

Bram Van Sassenbroeck via figshare.

Collection Method

Systematic literature review of cost-effectiveness analyses published since 2012.

Time Range

Studies from 2012 onward.

Freshness

Updated in April 2026.

Geography

General European population.